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Aims: Cardiac sarcoidosis (CS) is associated with a poor prognosis. Important 
features of CS include heart failure, conduction abnormalities and ventricular 
arrhythmias. Ventricular tachycardia (VT) is often refractory to antiarrhythmic drugs 
(AAD) and immunosuppression. Catheter ablation has emerged as a treatment option 
for recurrent VT. However, data on the efficacy and outcomes of VT ablation in this 
context are sparse. 
Methods: A systematic search was performed on PubMed, EMBASE and Cochrane 
database (from inception to September 2016) with included studies providing a 
minimum of information on CS patients undergoing VT ablation:  age, gender, VT 
cycle length, CS diagnosis criteria and baseline medications.  
 
Results: Five studies reporting on 83 patients were identified. The mean age of 
patients was 50±8 years, 53/30 (Males/Females) with a maximum of 56 patients 
receiving immunosuppressive therapy, mean ejection fraction was 39.1±3.1% and 
94% had an ICD in situ. The median number of VTs was 3 (2.6-4.9)/patient, mean 
cycle length of 360ms (326-400ms). 100% of VTs received endocardial ablation, and 
18% required epicardial ablation. The complication rates were 4.7-6.3%. Relapse 
occurred in 45 (54.2%) patients with an incidence of relapse 0.33 (95%CI 0.108-
0.551, p<0.004). Employing a less stringent endpoint (i.e. freedom from arrhythmia or 
reduction of ventricular arrhythmia burden), 61 (88.4%) patients improved following 
ablation. 
 
Conclusions: These data support the utilization of catheter ablation in selected CS 
cases resistant to medical treatment. However, data are derived from observational 
non-controlled case series, with low methodological quality. Therefore, future well-
designed, randomized controlled trials or large-scale registries are required. 
 





Sarcoidosis is a granulomatous multisystem disease of unknown aetiology 1, 2. Apart 
from the lymph nodes, central nervous system, skin, lungs and eyes, studies have 
shown that sarcoidosis can also affect the myocardium in about 2-5% of patients 3, 4. 
Cardiac sarcoidosis (CS) is associated with poor prognosis 1-4 5, and its clinical 
manifestations depend upon the location, extent and the activity of the disease. The 
“gold triad” that is normally identified in CS patients is: conduction system 
abnormalities, ventricular arrhythmias and heart failure 4 6.  
Ventricular tachycardia (VT) 7 is thought to be due to a re-entry mechanism 7, 8. 
However, triggered activity and abnormal automaticity have been observed with CS 
patients with reduction in arrhythmic burden after initiation of immunosuppression. 
This makes timing and acute management of ventricular arrhythmias in patients with 
active inflammation more challenging. Importantly, it is often refractory to 
antiarrhythmic drugs (AAD) immunosuppression, and frequently requires implantable 
cardioverter-defibrillator (ICD) according to current recommendations 7, 8.  
As recurrent VT is very common in CS and has impact on quality of life and 
prognosis, studies have investigated possible therapeutic approaches to abolish VT. 
Catheter ablation has emerged as a treatment option for recurrent VT over the last 
years 9, 10.  
In this article we aim to review the available data regarding to the efficacy and safety 









A systematic electronic search was performed on PubMed, EMBASE and Cochrane 
database (from inception to September 2016) with no language limitations, using the 
following search string: “ventricular tachycardia” AND (“ablation” OR “catheter 
ablation”) AND (“sarcoidosis” OR “sarcoid”).   
The population, intervention, comparison and outcome (PICO) approach was used 11. 
The population of interest included patients with CS, and the intervention was 
catheter ablation of VT. In the absence of a control group, a non-controlled 
observational analysis was performed. The primary outcome measure was VT 
recurrence post ablation. Procedural success was defined as freedom of VT (at the end 
of follow-up after a single ablation procedure). Other outcomes included: freedom 
from VT recurrence or reduction of arrhythmia burden; mortality; and heart transplant 
during follow-up. Assessed procedural complications were: procedural death, stroke, 
cardiac tamponade, acute myocardial infarction, major vascular complications, and 
“other life-threatening complications”, assessed on a study by study basis. 
In order to be included, studies needed to provide a minimum of information about 
the sample of CS patients undergoing catheter ablation of VT, namely age, gender, 
VT cycle length and number of morphologies, as well as information on the CS 
diagnosis criteria, and baseline medication. Observational non-controlled case series 
required a minimum of 5 patients to be considered eligible. 
Review articles, editorials and case reports, were not considered eligible for the 
purpose of this review. Patients with granulomatous diseases but without a confirmed 
diagnosis of sarcoidosis were excluded from the analysis.  
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Reference lists of all accessed full-text articles were further searched for sources of 
potentially relevant information. Authors of full-text papers were also contacted by 
email to retrieve additional information.  
Three independent reviewers (NP, RP and KB) screened all abstracts and titles to 
identify potentially eligible studies. The full text of these potentially eligible studies 
was then evaluated. Agreement of at least two reviewers was required for decisions 
regarding inclusion or exclusion of studies. Study quality was formally evaluated 
using the National Heart, Lung, and Blood Institute Quality Assessment Tool for Case 
Series Studies12 three reviewers (NP, RP KB). An agreement, between the three 
reviewers was mandatory for the final classification of studies. 
Data extraction and presentation for the preparation of this manuscript followed the 
recommendations of the PRISMA group 13. The following data were extracted for 
characterizing each patient sample in the selected studies, whenever available: study 
design, study population characteristics (age, gender), number and cycle length of 
VTs, follow-up duration, ablation procedure, definition of relapse, post-procedural 
monitoring, use of anti-arrhythmic agents. Patient-level data were obtained whenever 
these were available in the manuscripts or, after contacting authors.  
 
Statistical analysis 
Data were pooled using random-effects, according to the Mantel-Haenszel model, 
through Comprehensive Meta-Analysis software (Version 2). Overall incidences and 
95% confidence interval were estimated. 
Statistical heterogeneity on each outcome of interest was quantified using the I2 
statistic, which describes the percentage of total variation across studies due to 
heterogeneity rather than chance. Values of <25%, 25% to 50%, and >50% are by 
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Study selection and patient characteristics 
A total of 5 longitudinal studies meeting the inclusion criteria were identified. The 
selection process is illustrated in Figure 1 (PRISMA) and a total population of 83 
patients with CS undergoing VT ablation were included. The mean age of the patients 
was 50±8 y, 53/30 (Males/Females) with 56 receiving immunosuppressive therapy. 
The mean ejection fraction was 39.1±3.1% and 94% had an ICD in situ (baseline 
characteristics of patients are presented in Table 1). Overall mean or median number 
of VTs with which each patient presented per study was in the range of 2.6-4.9 with a 
mean cycle length in the range of 326-400ms.  
There was an excellent agreement between investigators on the inclusion of the 
selected studies. Baseline data and the design of selected trials, and diagnostic criteria 
of CS, are summarized in Tables 1 and S-Table 1, respectively. The diagnosis of CS 
was based on pathology data or Consensus/Guidelines, which differed slightly across 
studies (S-Table 1). Three studies 10, 14, 15 used the Guidelines of the Japanese 
Ministry of Health and Welfare16, while Dechering and colleagues 17 based the 
diagnosis of CS on the combination of pathologic identification of cardiac non-
caseating granulomas with clinical findings consistent with cardiac involvement. The 
most recent study of Muser et al. 18 used the criteria of the Heart Rhythm Society. So 
far, there are no accepted international guidelines for the diagnosis of CS. The two 
most commonly used guidelines are those of the Japanese Ministry of Health and 
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Welfare 16 and the National Institutes of Health’s A Case Control Etiology of 
Sarcoidosis Study set of criteria updated in 2014 by the World Association for 
Sarcoidosis and Other Granulomatous Disorders (WASOG)19. The most recent 
guidelines are those of the Heart Rhythm Society 20. All of them are in agreement that 
the diagnosis of CS can accurately be made only by the presence of non-caseating 
granuloma on histological examination of myocardial tissue with no alternative cause 
identified (including negative organismal stains if applicable). In addition, all three 
include clinical criteria, which are largely similar and could point towards the 
diagnosis of CS.  
The 5 studies used for the analysis, were all retrospective case series. All studies 
except for one 17 were single-centre, and were observational, with no control group 10, 
14, 15, 17, 18. According to the National Heart, Lung, and Blood Institute Quality 
Assessment Tool for Case Series Studies 12 there is maximum of 9 criteria which apply 
for case series as shown in S-Table 2. Four studies 10, 15, 17, 18 fulfilled 8 criteria, while 
one study 14 fulfilled 7 criteria.  
 
Procedural Data  
Of the 5 studies included in our analysis, only two studies 14, 18 reported on the 
duration of the procedure as well as the mean fluoroscopy time (Table 2). The 
CARTO mapping system was used in all studies, while a range of 3.5-8mm irrigated 
or non-irrigated tip catheters were used for mapping and ablation. Endocardial 
mapping was performed in all patients, whereas epicardial mapping was performed in 
25.3% (21) of patients. Substrate and VT mapping (for haemodynamically tolerated 
VTs) was performed in all studies. 
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Catheter ablation was performed using 25-50W, and 3 studies 10, 14, 18 targeted an 
impedance drop of at least 10 Ohm per lesion. Endocardial ablation was performed in 
all patients (100%), whereas epicardial ablation was performed in 15 patients (18%). 
Only 70% of patients (15 / 21) who underwent epicardial mapping were finally 
ablated from epicardium. All studies checked for inducible VTs at the end of the 
procedure and at least one VT morphology was still inducible in 36 patients (34%). 
Detailed procedural data are presented in Table 2. 
 
Efficacy of Catheter Ablation 
The mean follow-up period for 3 of the studies 14, 15, 17 was 19.6±13.5 months, while 
the remaining 2 studies 10, 18 had a median follow-up of 27 months. During the follow-
up period, at least one episode of recurrent VT occurred in 45 of the 83 (54.2%) 
patients undergoing catheter ablation. Twenty-six patients required a second ablation 
procedure, while 4 patients required a third ablation.  
Definition of VT relapse was similar across studies (S-Table 3). In 3 studies 14, 15, 17 
freedom from VT relapse was ≥50% after the first ablation procedure. Naruse et al.15 
reported the lowest relapse rate (43%) after a single procedure. In this study 4 patients 
(28.6%) required a second ablation procedure. Of those 4 patients, 3 patients whose 
initial ablation was directed at only scar-related VT had recurrence of scar-related VT. 
One patient whose initial ablation was directed at both scar- and Purkinje-related VT 
developed another focal Purkinje VT. On the contrary, Kumar et al. 10 reported the 
highest rate of relapse (71%) after first ablation, with a significant proportion of 
patients requiring a second (43%) or third ablation (10%).  
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Overall, the pooling of our data (Figure 2) shows that catheter ablation can be an 
effective method to diminish or abolish VTs in patients with CS, with an incidence of 
relapse 0.33 (95%CI 0.108-0.551, p<0.004). When a less stringent endpoint was used 
(i.e. freedom from arrhythmia or reduction of ventricular arrhythmia burden), 61 
(88.4%) patients improved following catheter ablation.  
 
Procedural complications 
It is worth mentioning that of the 5 studies, 2 studies 15, 17 did not provide any 
information related to procedural complications. One study 14, 17 claimed no 
complications during ablation and 2 studies 10, 18 reported on any form of complication 
(Table 3). More specifically, Kumar et al. 10 reported that a patient developed 
electromechanical dissociation and ultimately required a biventricular assistance 
device and later underwent heart transplant (Table 3). In addition, Muser et al. 18 
reported that one patient had perforation of the coronary sinus, while another one 
developed a total occlusion of a small coronary artery branch. The rate of procedural 
complications for each study did not exceed 4.7% to 6.4%, respectively. Overall, no 
procedural deaths were reported.  
 
Discussion 
In the present systematic review, we have shown that catheter ablation can decrease 
the overall ventricular arrhythmia burden in 88.4% of CS patients with recurrent VT, 
and render patients free from VT relapse in 45.8%. This was observed in cases where 
AAD and immunosuppression treatment could not prevent VT relapse. However, we 
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have found that 26 patients underwent a second procedure, while a third procedure 
was required in 4 patients.  
Although the results of VT ablation appear to be promising, the available data are 
limited, based on small cohort studies without controls and inherent poor quality. 
Despite those limitations, VT ablation in CS has quite comparable efficacy to VT 
ablation in other structural heart disease patients such ischemic cardiomyopathy 
(ICM) and non-ischemic dilated cardiomyopathy (NIDCM). The Multicenter 
Thermocool VT Ablation Trial 21 was a prospective observational trial that enrolled 
231 patients with recurrent monomorphic VT in setting of ICM treated with catheter 
ablation. After a follow-up of 6 months, it was found that 53 % of patients were free 
from recurrent incessant VT or intermittent VT. In the Ventricular Tachycardia 
Ablation in Coronary Heart Disease (VTACH) 22 study of the 107 patients included in 
the analysis, median time to VT/VF recurrence in the ablation group was longer than 
the control group (18.6 vs 5.9 months), while after 2 years, those randomised to 
ablation had superior VT/VF-free survival (47 vs 29 %; p=0.045). The data regarding 
to NIDCM are limited and without large prospective randomised trials describing the 
outcomes following VT ablation. One large single-centre retrospective observational 
study9, examined 119 patients with NIDCM and reported that 79 patients were free of 
VT after 12 months. Importantly, the Heart Center of Leipzig VT (HELP-VT) study 23 
which enrolled 63 patients with NIDCM and 164 patients with ICM demonstrated that 
the acute procedural success was achieved in 66.7 % of those with NIDCM (versus 
77.4 % in ICM; p=0.125). Long-term VT-free survival was significantly lower for 
NIDCM compared with ICM: VT-free survival rates at 1 year were 40.5 % for 
NIDCM and 57 % for ICM. Cumulative VT-free survival after median follow-up 
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periods of 20 and 27 months for NIDCM and ICM, respectively, were 23 % and 43 % 
(p=0.01).  
With regards to safety, the risk of complications may be as high as 6.4%, suggesting 
that the overall net benefit of the procedure may be acceptable, but appropriate patient 
selection and consenting is of utmost importance. Importantly, this risk rate appears to 
be comparable, or possibly lower, to the overall risk of complications (8-10%) from 
catheter ablation as this was assessed in a previous meta-analysis24.  
 
Therapeutic approaches targeting VT in patients with CS  
Typically, immunosuppression and antiarrhythmics are the first line treatments to 
manage VT in CS patients 20, 25. Corticosteroids along with steroid-sparing agents 
such as methotrexate, and cyclophosphamide are very often used 20, 25, 26. Studies have 
shown that corticosteroid therapy can be effective for managing ventricular 
arrhythmias at the early stage, but less effective at the late stage 27. However, the 
evidence for the role of immunosuppressive therapy is rather conflicting 28, 29. Muser 
et al. 18 suggested that patients with more inflammation at baseline are at higher risk 
of relapse. Therefore, a PET scan at baseline may be of importance to identify those 
individuals who are more likely to benefit from aggressive medical therapy. Although 
the optimal timing for ablation remains unclear, Muser et al. 18 recommend that a 
procedure should be performed after the active disease phase so as to achieve the best 
possible results. This is presumably due to the development of fibrosis in the substrate 
making it more amenable to ablation plus the lack of inflammatory infiltrate 
promoting automatic activity and forming new pro-arrhythmic sites. 
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Antiarrhythmic drugs such as amiodarone, mexiletine, β-blockers, lidocaine and 
others alone or in combination with immunosuppression therapy play a significant 
role in the management of VT in these patients 20. Despite the beneficial effects of 
corticosteroids, there are still data supporting that these could potentially result to 
worsening of VT when initiated shortly after the active phase 28, 29 or exert no effects 
at all 30. It has been suggested that treatment with steroids is effective mainly in early 
stages of the disease and before the development of overt clinical cardiac symptoms 
31. Heart transplantation is also an option in CS non-responsive to medical 
management, however it has been associated with increased mortality 20, 26. 
 
Ablation of ventricular tachycardia in cardiac sarcoidosis  
One of the issues of CS patients who are ICD recipients is the frequent occurrence of 
shocks and/or present with arrhythmia storms, in spite of medical therapy 32-34. The 
lack of effective non-invasive approaches to decrease the overall ventricular 
arrhythmia burden in this population has led to further investigation, pointing to 
catheter ablation as a possible approach for managing VT refractory to 
immunosuppressive and antiarrhythmic therapy. 
The pooling of our data suggests that catheter ablation of VT is an acceptable 
therapeutic option being effective in eradicating or decreasing the overall arrhythmia 
burden. However, the lack of a control group in all studies does not allow us to rule 
out the possibility of a placebo effect of ablation itself. 
Ventricular tachycardia in patients with CS is challenging. According to our data, 
several VT morphologies are usually identified. Endocardial mapping of both 
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ventricles is frequently required, with epicardial mapping and ablation needed in up to 
a third of procedures. More than a third of patients will require redo procedures, and 
complete VT eradication will occur only in half of patients. However, if we accept the 
broader endpoint of reduction of ventricular arrhythmia burden, 88.4% or even more 
than 90% of patients will experience some form of benefit. The possible occurrence of 
major complications in almost 5% of patients doesn’t make this a prohibitive 
procedure, but reinforces the need of careful patient selection. However, as shown 
before, recurrent VT in CS patients may be a surrogate of adverse prognosis, with 
death and transplant occurring in 6 and 9 patients respectively, in spite of ablation.  
Detailed endocardial and epicardial voltage mapping of CS patients shows confluent 
RV scarring with patchy LV involvement, with a predilection for the septum, anterior 
wall, and the outflow tracts 10. High-density mapping is important to better define scar 
areas, isthmuses and its wider adoption may result in better long-term procedural 
outcomes. A limitation of current mapping systems is to define to structural and 
functional substrates most likely to support VT and the inability to map intramural 
circuits. Potential approaches include the application of cardiac MRI (CMR) to 
identify potential channels in scar that can then be mapped and ablated as has been 
described in ARVC & IHD 35. This is critically dependent on image resolution with 
gadolinium late enhancement which will be reduced if the patient has an ICD as this 
reduces the resolution achievable by MRI since wide band image acquisition is 
required giving 4-8mm as opposed to 1mm sectioning of the substrate. This fact 
suggests the potential need of routine cardiac MRI scan in this population before 
implanting an ICD. 
Obtaining epicardial access may be a challenging process in less experienced centers, 
and is associated with peri-procedural complications. Possible indications for 
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mapping the epicardium are: persistent inducibility after endocardial ablation, 
recurrent VT following index ablation, 12-lead ECG suggesting epicardial origin, 
evidence of epicardial substrate on pre-procedural MRI, presence of unipolar 
electrogram abnormalities in the presence of normal bipolar electrogram voltage 18. 
Elimination of all inducible VTs is a difficult goal because of the diffuse and 
heterogeneous RV involvement, intramural scarring, or close proximity to critical 
epicardial structures, such as the coronary arteries, which prohibits ablation 10. The 
lack of ability to achieve transmural lesions for circuits deep in the septum or 
hypertrophied sites is a current limitation of ablation technology.  
Real-time contact force monitoring and aiming at higher force-time-integral values or 
ablation index may lead to more transmural lesion formation. Use of bipolar 
radiofrequency ablation 36, 37, transcoronary alcohol ablation 38, and needle catheter 
ablation 39 may be different alternatives for achieving transmural lesions, and 
neutralizing deep intramyocardial foci. Unfortunately, the benefit of these strategies 
has not yet been systematically assessed for CS patients 39. 
In the studies included in our systematic review, loss of pacing capture in the ablated 
tissue or drops in impedance during ablation were the strategies used to document 
successful RF delivery and lesion creation.  
Due to the intermittent nature of CS (active vs. inactive state), one of the main issues 
for cardiac electrophysiologists is the difference in VT inducibility between the 
inactive and active stages. One could argue that the main difficulty is actually not so 
much the intermittent nature, but the progressive and dynamic nature of the course of 
CS in some of these patients. The substrate is often changing and new arrhythmias 
may develop as well as recurrences may occur. Moreover, inability to map these 
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tachycardias due to their instability electrically/haemodynamically may indeed have 
an impact on long-term procedural success, but it may also reinforce the importance 
of medical therapy in the active phase to reduce inflammation and applying thorough 
substrate-based ablation with targeting and eradication of all late potential areas. 
To summarize, our findings suggest that even though VT ablation can be employed to 
CS patients with refractory VT, strong and high-quality data supporting its use and 
efficacy are absent. Data directly comparing VT ablation with pharmacologic therapy 
are missing. However, it is worth mentioning that in all studies, patients who did not 
respond to medical therapy, underwent catheter ablation. This indicates that ablation 
was reserved for the most severe and recurrent/refractory forms of VT. 
Randomization to catheter ablation versus medical therapy in such circumstances is 
not devoid of ethical issues, as it is unlikely physician would deny a patient the 
possibility of such a life-saving treatment option following unsuccessful non-invasive 
medical management. However, primary prevention ablation in cases of inducible VT 
following stabilisation with medical therapy especially in ICD candidates could be 
considered in a multicentre study. 
 
Limitations 
Several limitations in the analysis performed in the present systematic review need to 
be acknowledged. Firstly, we were not able to analyse data from case-control design 
due to the absence of control groups in all studies. Some studies included patients 
with CS not undergoing catheter ablation, as they were stable on medical therapy, and 
therefore these could not be classified as controls, as they appeared to have a less 
aggressive disease compared to those undergoing ablation (recurrent VT despite 
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medical therapy). Secondly, including single or dual-centre case series, and the large 
discrepancy in the demographic characteristics and medical management may explain 
part of the observed heterogeneity. Thirdly, missing data on concomitant medication, 
major events like death and/or transplantation during follow-up, outcomes of different 
ablation strategies (activation mapping vs substrate ablation) and procedural 
complications impact on the quality of the analyses. Fourthly, all included studies 
were conducted in centres with high levels of experience in VT ablation, and 
therefore the results of can only be extrapolated to centers with similar 
expertise. The results of VT ablation in sarcoid patients in low experience centres 
remain to be assessed, and in face of the complexity of the substrate, referral to 
highly experienced tertiary centers would be advisable. Systematic assessment 
of ablation through multicentre studies is required to evaluate the broad use of 
ablation as therapeutic approach in CS patients with refractory VT. Overall, the 
present data refer to patients with recurrent/refractory VT, and therefore cannot be 
extrapolated to all patients with sarcoidosis presenting with VT, namely the first 
episode of appropriate shock. 
 
Conclusions 
Data arising from small non-controlled cohort studies suggest that catheter ablation 
may be an important treatment option for refractory VT in CS patients. In fact, 
catheter ablation can result to acceptable rates of freedom from arrhythmia relapse in 
nearly 55% of patients in almost all studies, as well as to a reduction of arrhythmia 
burden in 88% (or more) of patients. Moreover, freedom from arrhythmia in almost 
half of patients occurs at the expense of a non-negligible (up to 5%) rate of major 
complications. However, studies on this topic are observational non-controlled case 
17 
 
series, with low methodological quality. Therefore, future well-designed randomized 
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Figure 1. Flowchart diagram illustrating study selection methodology. 
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